Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Sanjay Hadigal, Laura Colombo & Scott Haughie. (2023) Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”. Human Vaccines & Immunotherapeutics 19:2.
Read now
Read now
Antonio Arbo, Celia Martinez-Cuellar, Cynthia Vazquez, Lucile Bellier, Cecilia Adorno, Hugo Dibarboure, Juan Guillermo Lopez, Audrey Petitjean & Pablo Bianculli. (2022) Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Cecilia Trucchi, Marco D’Amelio, Daniela Amicizia, Andrea Orsi, Idalba Loiacono, Roberta Tosatto, Maria Francesca Piazza, Chiara Paganino, Andrea Pitrelli, Giancarlo Icardi & Filippo Ansaldi. (2021) Lowering the recommended age for the free and active offer of influenza vaccination in Italy: clinical and economic impact analysis in the Liguria region. Human Vaccines & Immunotherapeutics 17:5, pages 1387-1395.
Read now
Read now
Jesús Ruiz-Aragón, Ray Gani, Sergio Márquez & Piedad Alvarez. (2020) Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain. Human Vaccines & Immunotherapeutics 16:9, pages 2238-2244.
Read now
Read now
Francesco Saverio Mennini, Chiara Bini, Andrea Marcellusi, Alessandro Rinaldi & Elisabetta Franco. (2018) Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy. Human Vaccines & Immunotherapeutics 14:8, pages 1867-1873.
Read now
Read now
Viviane Gresset-Bourgeois, Phillip S. Leventhal, Stéphanie Pepin, Rosalind Hollingsworth, Marie-Pierre Kazek-Duret, Iris De Bruijn & Sandrine I. Samson. (2018) Quadrivalent inactivated influenza vaccine (VaxigripTetra™). Expert Review of Vaccines 17:1, pages 1-11.
Read now
Read now
Riju Ray, Gaël Dos Santos, Philip O. Buck, Carine Claeys, Gonçalo Matias, Bruce L. Innis & Rafik Bekkat-Berkani. (2017) A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Human Vaccines & Immunotherapeutics 13:7, pages 1640-1652.
Read now
Read now
Pieter T. de Boer, Britt M. van Maanen, Oliver Damm, Bernhard Ultsch, Franklin C.K. Dolk, Pascal Crépey, Richard Pitman, Jan C. Wilschut & Maarten J. Postma. (2017) A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research 17:3, pages 249-265.
Read now
Read now
Articles from other publishers (30)
Lauren Brown, Kelly J Sutton, Chantelle Browne, José Bartelt-Hofer, Wolfgang Greiner, Audrey Petitjean & Julie Roiz. (2023) Cost of illness of the vaccine-preventable diseases influenza, herpes zoster and pneumococcal disease in France. European Journal of Public Health.
Crossref
Crossref
Clara R. Warmath, Ismael R. Ortega-Sanchez, Lindsey M. Duca, Rachael M. Porter, Molly G. Usher, Joseph S. Bresee, Kathryn E. Lafond & William W. Davis. (2023) Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review. Value in Health 26:5, pages 768-779.
Crossref
Crossref
Jesús Ruiz-Aragón & Sergio Márquez-Peláez. (2023) An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain. Vaccines 11:2, pages 427.
Crossref
Crossref
Bronke Boudewijns, John Paget, Marco Del Riccio, Laurent Coudeville & Pascal Crépey. (2022) Preparing for the upcoming 2022/23 influenza season: A modelling study of the susceptible population in Australia, France, Germany, Italy, Spain and the United Kingdom. Influenza and Other Respiratory Viruses 17:1.
Crossref
Crossref
Giovanna Elisa Calabrò, Floriana D’Ambrosio, Elettra Fallani & Walter Ricciardi. (2022) Influenza Vaccination Assessment according to a Value-Based Health Care Approach. Vaccines 10:10, pages 1675.
Crossref
Crossref
Desmond Loong, Ba’ Pham, Mohammadreza Amiri, Hailey Saunders, Sujata Mishra, Amruta Radhakrishnan, Myanca Rodrigues, Man Wah Yeung, Matthew P. Muller, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults. Value in Health 25:8, pages 1439-1458.
Crossref
Crossref
Saja A. Alnahar, Georgios Gkountouras, Rula M. Darwish & Ian Bates. (2022) Community pharmacists workforce readiness to deliver vaccination services: A cross‐sectional study from Jordan. Pharmacology Research & Perspectives 10:2.
Crossref
Crossref
Jesús Ruiz-Aragón, Sergio Márquez-Peláez, Ray Gani, Piedad Alvarez & Richard Guerrero-Luduena. (2022) Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain. Vaccines 10:2, pages 176.
Crossref
Crossref
Raul Ortiz de Lejarazu-Leonardo, Emanuele Montomoli, Radek Wojcik, Solomon Christopher, Anne Mosnier, Elena Pariani, Antoni Trilla Garcia, Helmut Fickenscher, Barbara C. Gärtner, Ravi Jandhyala, Maria Zambon & Catherine Moore. (2021) Estimation of Reduction in Influenza Vaccine Effectiveness Due to Egg-Adaptation Changes—Systematic Literature Review and Expert Consensus. Vaccines 9:11, pages 1255.
Crossref
Crossref
Yonghong Liu, Shirin Strohmeier, Irene González-Domínguez, Jessica Tan, Viviana Simon, Florian Krammer, Adolfo García-Sastre, Peter Palese & Weina Sun. (2021) Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. Frontiers in Immunology 12.
Crossref
Crossref
Sylwia Kałucka & Izabela Grzegorczyk-Karolak. (2021) Barriers Associated with the Uptake Ratio of Seasonal Flu Vaccine and Ways to Improve Influenza Vaccination Coverage among Young Health Care Workers in Poland. Vaccines 9:5, pages 530.
Crossref
Crossref
Marga Janse, Thomas Brouwers, Eric Claassen, Peter Hermans & Linda van de Burgwal. (2021) Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D. Frontiers in Public Health 9.
Crossref
Crossref
T.K. Teoh, J. Powell, J. Kelly, C. McDonnell, R. Whelan, N.H. O'Connell & C.P. Dunne. (2021) Outcomes of point-of-care testing for influenza in the emergency department of a tertiary referral hospital in Ireland. Journal of Hospital Infection 110, pages 45-51.
Crossref
Crossref
Sylwia Kałucka, Agnieszka Głowacka, Elżbieta Dziankowska-Zaborszczyk & Izabela Grzegorczyk-Karolak. (2021) Knowledge, Beliefs and Attitudes towards the Influenza Vaccine among Future Healthcare Workers in Poland. International Journal of Environmental Research and Public Health 18:4, pages 2105.
Crossref
Crossref
Florian Zeevat, Pascal Crépey, F. Christiaan K. Dolk, Arjan J. Postma, Vidya N.A. Breeveld-Dwarkasing & Maarten J. Postma. (2021) Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program. Value in Health 24:1, pages 3-10.
Crossref
Crossref
Marcin Czech, Marcin Balcerzak, Adam Antczak, Michał Byliniak, Elżbieta Piotrowska-Rutkowska, Mariola Drozd, Grzegorz Juszczyk, Urszula Religioni, Regis Vaillancourt & Piotr Merks. (2020) Flu Vaccinations in Pharmacies—A Review of Pharmacists Fighting Pandemics and Infectious Diseases. International Journal of Environmental Research and Public Health 17:21, pages 7945.
Crossref
Crossref
Angela Choi, Adolfo García-Sastre & Michael Schotsaert. (2020) Host immune response–inspired development of the influenza vaccine. Annals of Allergy, Asthma & Immunology 125:1, pages 28-35.
Crossref
Crossref
Pascal Crépey, Esther Redondo, Javier Díez-Domingo, Raúl Ortiz de Lejarazu, Federico Martinón-Torres, Ángel Gil de Miguel, Juan Luis López-Belmonte, Fabián P. Alvarez, Hélène Bricout & Míriam Solozabal. (2020) From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain. PLOS ONE 15:5, pages e0233526.
Crossref
Crossref
Helena C. MaltezouAthanassios KossyvakisTheodore LytrasMaria ExindariMaria ChristoforidiAndreas MentisGeorgia Gioula. (2020) Circulation of Influenza Type B Lineages in Greece During 2005–2015 and Estimation of Their Impact. Viral Immunology 33:2, pages 94-98.
Crossref
Crossref
Patrick Tjok Joe, Ioanna Christopoulou, Lien van Hoecke, Bert Schepens, Tine Ysenbaert, Carlo Heirman, Kris Thielemans, Xavier Saelens & Joeri L. Aerts. (2019) Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice. Journal of Translational Medicine 17:1.
Crossref
Crossref
Martina Havlickova, Sophie Druelles, Helena Jirincova, Radomira Limberkova, Alexander Nagy, Anvar Rasuli & Jan Kyncl. (2019) Circulation of influenza A and B in the Czech Republic from 2000-2001 to 2015-2016. BMC Infectious Diseases 19:1.
Crossref
Crossref
Alberto Pérez-Rubio, Leticia Platero & José María Eiros Bouza. (2019) Gripe estacional en España: carga clínica y económica y programas de vacunación. Medicina Clínica 153:1, pages 16-27.
Crossref
Crossref
Alberto Pérez-Rubio, Leticia Platero & José María Eiros Bouza. (2019) Seasonal influenza in Spain: Clinical and economic burden and vaccination programmes. Medicina Clínica (English Edition) 153:1, pages 16-27.
Crossref
Crossref
Bozidarka Rakocevic, Anita Grgurevic, Goran Trajkovic, Boban Mugosa, Sandra Sipetic Grujicic, Sanja Medenica, Olivera Bojovic, José Eugenio Lozano Alonso & Tomas Vega. (2019) Influenza surveillance: determining the epidemic threshold for influenza by using the Moving Epidemic Method (MEM), Montenegro, 2010/11 to 2017/18 influenza seasons. Eurosurveillance 24:12.
Crossref
Crossref
Bruno Simon, Maxime Pichon, Martine Valette, Gwendolyne Burfin, Mathilde Richard, Bruno Lina & Laurence Josset. (2019) Whole Genome Sequencing of A(H3N2) Influenza Viruses Reveals Variants Associated with Severity during the 2016–2017 Season. Viruses 11:2, pages 108.
Crossref
Crossref
E. Redondo, I. Rivero-Calle, D.A. Vargas, E. Mascarós, J.L. Díaz-Maroto, M. Linares, A. Gil, J. Molina, I. Jimeno, D. Ocaña, J.E. Yuste & F. Martinón-Torres. (2018) Vacunación frente a la neumonía adquirida en la comunidad del adulto. Actualización 2018 del posicionamiento del Grupo de Neumoexpertos en Prevención. Medicina de Familia. SEMERGEN 44:8, pages 590-597.
Crossref
Crossref
José Antonio López Trigo, Rosa López Mongil, Alberto Mariano Lázaro, Gloria Mato Chaín, Norberto Moreno Villajos & Primitivo Ramos Cordero. (2018) Vacunación frente a la gripe estacional en las personas mayores. Evaluación de la vacuna tetravalente. Informe de posicionamiento. Revista Española de Geriatría y Gerontología 53, pages 185-202.
Crossref
Crossref
A. García, M. Fernández-Prada, J. Aristegui, D. Moreno, E. Redondo, I. Jimeno, M. García Cenoz & J.A. Lopez Trigo. (2018) Executive summary of the update and reflection document on influenza vaccination in Spain. Vacunas (English Edition) 19:2, pages 85-98.
Crossref
Crossref
A. García, M. Fernández-Prada, J. Aristegui, D. Moreno, E. Redondo, I. Jimeno, M. García Cenoz & J.A. Lopez Trigo. (2018) Resumen ejecutivo del documento de actualización y reflexión sobre vacunación antigripal en España. Vacunas 19:2, pages 85-98.
Crossref
Crossref
Emanuele Montomoli, Alessandro Torelli, Ilaria Manini & Elena Gianchecchi. (2018) Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults. Vaccines 6:1, pages 14.
Crossref
Crossref